Proximal tubule sphingosine kinase-1 has a critical role in A1 adenosine receptor-mediated renal protection from ischemia  by Park, Sang W. et al.
Proximal tubule sphingosine kinase-1 has a critical
role in A1 adenosine receptor-mediated renal
protection from ischemia
Sang W. Park1, Mihwa Kim1, Joo Y. Kim1, Kevin M. Brown1, Volker H. Haase2, Vivette D. D’Agati3
and H. Thomas Lee1
1Department of Anesthesiology, Columbia University, New York, New York, USA; 2Division of Nephrology and Hypertension,
Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA and 3Department of Pathology, Columbia University,
New York, New York, USA
Renal ischemia–reperfusion injury is a major cause of acute
kidney injury. We previously found that renal A1 adenosine
receptor (A1AR) activation attenuated multiple cell death
pathways including necrosis, apoptosis, and inflammation.
Here, we tested whether induction of cytoprotective
sphingosine kinase (SK)-1 and sphingosine-1-phosphate
(S1P) synthesis might be the mechanism of protection.
A selective A1AR agonist (CCPA) increased the synthesis of
S1P and selectively induced SK1 in mouse kidney and
HK-2 cells. This agonist failed to protect SK1-knockout
but protected SK2-knockout mice against renal
ischemia–reperfusion injury indicating a critical role of SK1 in
A1AR-mediated renal protection. Inhibition of SK prevented
A1AR-mediated defense against necrosis and apoptosis in
HK-2 cells. A selective S1P1R antagonist (W146) and global
in vivo gene knockdown of S1P1Rs with small interfering RNA
completely abolished the renal protection provided by CCPA.
Mice selectively deficient in renal proximal tubule S1P1Rs
(S1P1R
f/f PEPCKCre/–) were not protected against renal
ischemia–reperfusion injury by CCPA. Mechanistically, CCPA
increased nuclear translocation of hypoxia-inducible factor-
1a in HK-2 cells and selective hypoxia-inducible factor-1a
inhibition blocked A1AR-mediated induction of SK1. Thus,
proximal tubule SK1 has a critical role in A1AR-mediated
protection against renal ischemia–reperfusion injury.
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Renal ischemia–reperfusion (IR) injury is a frequent cause of
acute kidney injury (AKI).1 AKI a major clinical problem
often leading to multi-organ dysfunction and systemic
inflammation with extremely high mortality.2 Unfortunately,
the severity and incidence of AKI has been increasing without
any improvements in therapy or patient survival over the past
50 years.3 Currently, the incidence of renal dysfunction after
major surgery in high-risk patients has been reported to be as
high as 70–80%.4–6 Despite continued research on renal
protective strategies, there are no proven therapies to reduce
AKI in the perioperative setting.
We have previously demonstrated that A1 adenosine
receptor (A1AR) activation reduced necrosis and apoptosis
in cultured proximal tubule cells.7,8 Moreover, A1AR
activation immediately before renal ischemia protected
against renal IR injury in rats and mice in vivo.9,10
In addition to reduction in renal necrosis and apoptosis,9,11
we also observed a surprising reduction in renal inflamma-
tion (reduced leukocyte influx and pro-inflammatory
cytokine upregulation) as an important component of renal
protection with A1AR activation. Unlike the better character-
ized and traditionally understood anti-inflammatory mech-
anisms of A2aARs, the anti-inflammatory mechanisms of
A1ARs remain unclear. Therefore, we hypothesized that A1AR
activation may induce additional mediator(s) that produce
direct anti-inflammatory effects to protect against renal IR.
Phosphorylation of sphingosine by two subtypes of
sphingosine kinase (SK1 and SK2) leads to the formation
of sphingosine-1-phosphate (S1P), a lysophospholipid tar-
geting G-protein coupled receptors with diverse extracellular
as well as intracellular effects.12–14 In particular,
renal tubular SK1 activation has been shown to produce
renoprotection after IR.15–17 Moreover, of five G-protein
coupled S1P receptors (S1PRs), S1P1R activation has been
shown to counteract against cardiac18,19 and renal IR
injury17,20 and attenuates T-lymphocyte-mediated tissue
inflammation.13,21,22 Furthermore, S1P1R agonists produce
renal protection via direct activation of S1P1Rs in renal
proximal tubules.23
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In this study, we tested the hypothesis that renal tubular
A1AR activation produces anti-inflammatory and cytopro-
tective S1P via activation of renal proximal tubule SK. We
utilized genetically modified strains of mice lacking SK1
(SK1/) and SK2 (SK2/) enzyme. In addition, we tested
that activation of S1P1R via A1AR–mediated S1P generation
is critical in renal protection utilizing mice treated with a
selective S1P1R antagonist (W146) as well as mice treated
with small interfering RNA (siRNA) designed for in vivo
targeting of S1P1R. To investigate the direct involvement of
proximal tubule S1P1R in A1AR agonist-mediated renal
protection in vivo, we generated mice with proximal tubule-
specific deletion of S1P1R by crossing mice carrying the
floxed S1P1R gene
12 with mice expressing Cre recombinase
under the control of the phosphoenolpyruvate carboxykinase
promoter.24 Finally, we examined the mechanisms of
A1AR–mediated renal proximal tubule SK activation. Utiliz-
ing cultured human proximal tubule cells in vitro, we tested
the hypothesis that hypoxia-inducible factor-1a (HIF-1a) has
a critical role in mediating A1AR–mediated induction of SK1.
RESULTS
A1AR activation or overexpression increases SK1 synthesis
and induces SK activity in mouse kidney
We initially tested whether A1AR activation increased SK1
expression and activity in mouse kidney (cortex and
corticomedullary junction). Figure 1a and b show that a
selective A1AR agonist 2-chloro-N6-cyclopentyladenosine
(CCPA) (0.1 mg/kg, intraperitoneal (i.p.)) increased SK1
mRNA (measured at 6 h) and protein expression (measured
at 16 h) and upregulated SK activity (measured at 6 h) in
mouse kidney. In contrast, the A1AR agonist CCPA failed to
increase SK2 synthesis in mouse kidney. We measured
preferentially SK1 activity by adding Triton x-100 in our
SK activity assay as described by Vessey et al.25
Next, we aimed to determine whether overexpression of
renal A1ARs increased SK1 expression in mouse kidney.
We previously demonstrated that intrarenal A1AR–enhanced
green fluorescent protein (EGFP) lentivirus transduction
resulted in a selective and robust A1AR overexpression in
the injected kidneys within 48 h.26 In this study, we show
that kidneys injected with A1AR–EGFP lentivirus 48 h
prior showed increased SK1 mRNA and protein expression
compared with EGFP lentivirus-injected kidneys (Figure 1c).
SK2 mRNA expression did not change with A1AR–EGFP
lentivirus injection.
SK1 activation is critical for A1AR–mediated protection
against renal IR
Next, we tested whether SK1 activation is critical in
A1AR–mediated protection against renal IR. Plasma creati-
nine values were similar between sham-operated (anesthesia,
laparotomy, right nephrectomy and recovery) wild-type
(WT) creatinine (Cr)¼ 0.4±0.03 mg/dl, N¼ 3), SK1/
(SK1 knockout, Cr¼ 0.4±0.06 mg/dl, N¼ 3), and SK2/
(SK2 knockout, Cr¼ 0.4±0.09 mg/dl, N¼ 3) mice. Plasma
creatinine increased in WT, SK1/, and SK2/ mice
subjected to 30-min renal IR compared with sham-operated
mice (Figure 2a). As we described previously, SK1/ and
SK2/ mice had slightly increased and decreased renal
injury, respectively, compared with WT mice.17 Treatment
with CCPA significantly attenuated the increases in plasma
creatinine in WT and SK2/ mice but not in SK1/ mice
(Figure 2a). Figure 2b demonstrates increased histological
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Figure 1 |A1 adenosine receptor (A1AR) activation or overexpression increases sphingosine kinase (SK)-1 expression and activity
in mouse kidney. (a) Representative bands for SK1 and SK2 mRNA (reverse transcription (RT)-PCR, 6 h) and protein (immunoblotting,
16 h) expression in mouse kidney treated with vehicle (0.4% dimethyl sulfoxide (DMSO) in saline) or 2-chloro-N6-cyclopentyladenosine
(CCPA) (0.1mg/kg, intraperitoneal (i.p.)) (N¼ 4 for each group). (b) Mouse kidney SK activity 6 h after vehicle (0.4% DMSO) or CCPA (0.1mg/
kg, i.p.) treatment (N¼ 4 for each group). Data are presented as means±s.e.m. *Po0.05 vs. vehicle-treated mice. (c) Representative bands
for SK1 and SK2 mRNA (RT-PCR) and SK1 protein (immunoblotting) expression in mouse kidney injected with enhanced green fluorescent
protein (EGFP) or A1AR–EGFP lentivirus 48 h prior (N¼ 4 for each group). GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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injury in WT mice 24 h after renal IR. Compared with
sham-operated mice (not shown), the kidneys of
WT mice subjected to renal IR showed significant tubular
vacuolization, proteinaceous casts with increased tubular
dilatation, congestion, and simplification (Figure 2b).
Consistent with the plasma creatinine data, WT mice or
SK2/ mice treated with CCPA had reduced renal
necrosis and tubular injury (Figure 2c and e). In contrast,
SK1/ mice were not protected with CCPA and continued
to show histological signs of severe renal tubular injury
(Figure 2d).
The Jablonski scale27 renal injury score (RIS) histology
grading was used to grade renal tubular necrosis 24 h after
renal IR (Figure 2f). At 30 min of renal ischemia and 24 h
of reperfusion resulted in severe acute tubular necrosis in
vehicle-treated WT, SK1/, or SK2/ mice. In contrast,
WT or SK2/ mice treated with CCPA had significantly
lower RISs compared with vehicle-treated mice subjected to
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renal IR. Consistent with plasma creatinine and histology
data, SK1/ mice treated with CCPA failed to improve the
RIS (Figure 2f).
Our data also demonstrate that a selective A1AR agonist
CCPA-induced SK1, HIF-1a as well as heat shock protein
27 (HSP27) and reduced pro-inflammatory mRNA (inter-
cellular adhesion molecule-1 and tumor necrosis factor-a
(TNF-a)) expression in kidneys from WT mice but not in
kidneys from SK1/ mice (SK1 knockout, Figure 2g).
Finally, we show that CCPA reduced neutrophil infiltration in
kidneys from WT and SK2/ mice but not in kidneys from
SK1/ mice (Figure 2h–k). Therefore, CCPA-mediated
reduction in renal inflammation (pro-inflammatory
intercellular adhesion molecule-1 and TNF-a mRNA
expression and neutrophil infiltration) requires SK1.
Finally, WT mice renally injected with A1AR–EGFP
lentivirus 48 h prior were protected against renal IR injury
(Figure 2l) when compared with EGFP-injected WT mice.
Consistent with the hypothesis that A1AR–mediated
induction of SK1 mediates the renal protection in A1AR–
EGFP renally injected mice, SK1/ renally injected with
A1AR–EGFP lentivirus were not protected against renal
IR when compared with EGFP-injected SK1/ mice.
In contrast, SK2/ mice were protected against renal IR
after A1AR–EGFP lentivirus injection (Figure 2l).
Critical role of S1P1R in A1AR–mediated protection
against renal IR
We first treated WT mice with a selective S1P1R antagonist
W146 or with an siRNA designed for in vivo targeting of
S1P1R. Figure 3a demonstrates significantly reduced S1P1R
mRNA expression in the kidneys of mice treated with siRNA
targeting S1P1R compared with scrambled control siRNA-
treated mice. Other S1PR mRNAs (S1P2R, S1P3R, S1P4R, and
S1P5R) in the kidney were not affected by S1P1R siRNA
treatment.
A selective A1AR agonist (CCPA) failed to protect against
renal IR injury in mice treated with an antagonist for S1P1R
(W146) or with S1P1R siRNA (Figure 3b). Significant renal
injury was evident in mice treated with W146 or S1P1R siRNA
and subjected to renal IR (Figure 3c and e) with severe tubular
necrosis, corticomedullary congestion and hemorrhage, and
development of proteinaceous casts (30-min renal ischemia
and 24-h reperfusion). Importantly, both W146 as well as
S1P1R siRNA prevented the renal protection provided by
CCPA (Figure 3d and f). The Jablonski scale RIS histology
grading also confirmed lack of CCPA-mediated renal protec-
tion in W146 or S1P1R siRNA-treated mice (Figure 3g).
Critical role of renal proximal tubule S1P1R in
A1AR–mediated renal protection
To investigate the direct involvement of proximal tubule
S1P1R in A1AR agonist-mediated renal protection after IR,
we generated mice with proximal tubule-specific deletion of
S1P1R by crossing mice carrying the floxed S1P1R gene
(S1P1R
f/f mice, provided by Dr Richard Proia (NIH))12 with
PEPCKCre recombinase mice (Cre recombinase under the
control of the phosphoenolpyruvate carboxykinase promoter,
provided by Dr Volker Haase, Vanderbilt University).24 The
PEPCKCre transgenic mice haveB10-fold increase in PEPCK
expression in renal proximal tubules.24 Mating S1P1R
f/f mice
with PEPCKCre/ mice resulted in mice carrying floxed S1P1R
with (null) or without (WT) PEPCK Cre recombinase.
Tail PCR confirmed the genotypes of proximal tubule-
specific S1P1R null mice (S1P1R
f/f PEPCKCre/) and the
control transgenic mice (S1P1R
f/f or PEPCKCre/) generated
Figure 2 | Sphingosine kinase (SK)-1 is critical for A1 adenosine receptor (A1AR)–mediated renal protection against ischemic acute
kidney injury (AKI). (a) Plasma creatinine levels (24 h after surgery) from wild-type (WT), SK1/ (SK1 knockout (KO)), or SK2/ (SK2 KO)
mice subjected to sham surgery (N¼ 4) or to renal ischemia–reperfusion (IR) after vehicle (0.4% dimethyl sulfoxide (DMSO) in saline) or a
selective A1AR agonist treatment (2-chloro-N6-cyclopentyladenosine (CCPA), 0.1mg/kg, intraperitoneal (i.p.) 15min before renal ischemia)
treatment (N¼ 6 for each group). Treatment with CCPA significantly attenuated the increases in plasma creatinine in WT and SK2/ mice
but not in SK1/mice. *Po0.05 vs. vehicle-treated mice subjected to sham surgery. #Po0.05 vs. vehicle-treated mice subjected to renal IR.
(b–e) Representative photomicrographs (magnification  200) hematoxylin and eosin staining of kidney sections of mice subjected to
30min of renal ischemia followed by 24 h of reperfusion. Photographs are representative of four independent experiments. Vehicle-treated
WT mice (WT vehicle IR) showed severe renal tubular necrosis after renal IR (b). CCPA treatment significantly attenuated renal IR injury in WT
(c) and SK2/ mice (e) but not in SK1/ (d) mice. (f) Summary of Jablonski scale renal injury scores (RISs) (scale 0-4) for mice subjected to
sham operation or renal IR. #Po0.05 vs. vehicle-treated mice subjected to renal IR. Error bars represent 1 s.e.m. (g) Representative reverse
transcription (RT)-PCR bands of TNF-a, intercellular adhesion molecule-1 (ICAM-1), SK1, hypoxia-inducible factor-1a (HIF-1a), and heat shock
protein 27 (HSP27) mRNA in the kidney tissues from SK1þ /þ (WT) or SK1/ (knockout (KO)) mice (N¼ 4 for each group). Mice were treated
with vehicle (0.4% DMSO in saline) or with a selective A1AR agonist (CCPA, 0.1mg/kg, i.p. 15min before renal ischemia or sham operation)
and then subjected to sham operation or to 30min of renal ischemia and 5 h of reperfusion. Treatment with CCPA-induced SK1 and HSP27
mRNA and reduced induction of pro-inflammatory TNF-a and ICAM-1 mRNA expression after renal IR in SK1þ /þ mice but not in SK1/
mice. (h–k) Representative immunohistochemistry (magnification  200) for neutrophil infiltration of kidney sections of mice subjected to
30min of renal ischemia followed by 24 h of reperfusion. Photographs are representative of four independent experiments. Vehicle-treated
wild-type mice (WT vehicle IR, h) showed many neutrophils after renal IR. CCPA treatment attenuated neutrophil infiltration in WT (i)
and SK2/ mice (k) but not in SK1/ (j) mice. Secondary antibody conjugated to horseradish peroxidase was developed with
diaminobenzidine to stain neutrophils dark brown. (l) WT and mice deficient in SK1 or SK2 were renally injected with lentivirus encoding
enhanced green fluorescent protein (EGFP) or A1AR–EGFP 48 h prior. WT mice renally injected with A1AR–EGFP lentivirus were protected
against renal IR injury (N¼ 4) when compared with EGFP-injected WT mice (N¼ 4). In contrast, SK1/ mice (SK1 KO) renally injected
with A1AR–EGFP lentivirus were not protected against renal IR (N¼ 4) when compared with EGFP-injected SK1/ mice (N¼ 4). In contrast,
SK2/ (SK2 KO) mice were protected against renal IR after A1AR–EGFP lentivirus injection (N¼ 4). *Po0.05 vs. EGFP-injected subjected to
renal IR. #Po0.05 vs. A1AR–EGFP–injected mice subjected to renal IR. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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(Figure 4a). To confirm selective deletion of S1P1R in renal
proximal tubules from S1P1R
f/f PEPCKCre/ mice, S1P1R
mRNA levels in freshly isolated proximal tubules (with
percoll gradient separation)28 as well as in kidney cortex,
inner medulla, liver, and lung were measured with conven-
tional and real-time reverse transcription-PCR. A represen-
tative gel image of PCR products and the quantified mRNA
levels (Figure 4b) show a drastically decreased S1P1R mRNA
(490%) in renal cortex and proximal tubules from proximal
tubule-specific S1P1R null mice (S1P1R
f/f PEPCKCre/)
compared with the WT control (S1P1R
f/f PEPCK /) mice.
S1P1R mRNA levels in the kidney inner medulla, liver, and
lung did not change with proximal tubule-specific
S1P1R deletion. Other S1PR subtypes (S1P25R) also did
not change with proximal tubule-specific S1P1R deletion
(data not shown). We also crossed PEPCKCre mice with
ROSA26Sortm4(ACTBtdTomato,EGFP)Luo/J mice to confirm specific
Cre recombinase activity. Figure 4c shows kidney EGFP
reporter immunofluorescence expression indicative of Cre
recombinase activity in ROSA26Sortm4(ACTBtdTomato,
EGFP)Luo/J mouse crossed with PEPCKCre/ mouse.
Figure 4d shows plasma creatinine from WT (S1P1R
f/f
PEPCK/) or from proximal tubule-specific S1P1R null
mice (S1P1R
f/f PEPCKCre/) subjected to 30 min of renal
ischemia and 24 h of reperfusion. Treatment with a selective
A1AR agonist (CCPA, 0.1 mg/kg, i.p. 15 min before renal
ischemia) did not protect against ischemic AKI in proximal
tubule S1P1R null mice subjected to renal IR. Lack of
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Figure 3 |Critical role of S1P1R in A1 adenosine receptor (A1AR)–mediated protection against renal ischemia–reperfusion (IR).
(a) Evidence for in vivo knockdown of the S1P1R with small interfering RNA (siRNA) treatment. Representative reverse transcription (RT)-PCR
bands of S1PR subtype mRNA (normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH)) in mouse kidney treated with scramble
siRNA or siSTABLE targeting S1P1R. Mice were injected with scrambled control siRNA or siRNA targeting the S1P1R 48 h prior. Mice injected
with siSTABLE targeting S1P1R show selective reduction in S1P1R mRNA without affecting S1P2–5R mRNAs. (b) Plasma creatinine levels from
mice treated with vehicle (0.4% dimethyl sulfoxide (DMSO) in saline) or with a selective A1AR agonist (2-chloro-N6-cyclopentyladenosine
(CCPA), 0.1mg/kg, intraperitoneal (i.p.)) and subjected to sham operation or to 30min of renal ischemia and 24 h of reperfusion. A selective
S1P1R antagonist (W146, 0.1mg/kg, i.p., 15min before renal ischemia) or siRNA for S1P1R (50mg intravenous (i.v.), 48 h before renal
ischemia) prevented renal protection achieved with CCPA (N¼ 4–6 for each group). (c–g) Representative photomicrographs (c–f, N¼ 4 for
each group, magnification  200) and renal injury scores (RISs) (g) of hematoxylin and eosin staining of kidney sections of mice treated with
W146 (c, d) or with siRNA for S1P1R (e, f). Blockade of S1P1R with W146 or in vivo knockdown of S1P1R prevented CCPA-mediated protection
against necrosis. Data are presented as means±s.e.m. siSTABLE, stability-enhanced siRNA.
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Figure 4 |Critical role of renal proximal tubule S1P1R in A1 adenosine receptor (A1AR)–mediated protection against renal
ischemia–reperfusion (IR). (a) Tail PCR confirming the genotypes of proximal tubule-specific S1P1R null mice (S1P1R
f/f PEPCKCre/ or S1P1R
f/
PEPCKCre/) and the control transgenic mice (S1P1R
f/f or PEPCKCre/). (b) Selective deletion of S1P1R in renal proximal tubules in S1P1R
f/f
PEPCKCre/ mice. S1P1R mRNA levels in freshly isolated proximal tubules as well as in kidney cortex, inner medulla, liver and lung were
measured with conventional (left panel, representative gel image of PCR products) and real time (right panel) reverse transcription (RT)-PCR.
Proximal tubule-specific S1P1R null mice (S1P1R
f/f PEPCKCre/) show a drastically decreased S1P1R mRNA (490%) in renal cortex and
proximal tubules compared with the wild-type (WT) control (S1P1R
f/f PEPCK/) mice. S1P1R mRNA levels in the kidney
inner medulla, liver, and lung did not change with proximal tubule-specific S1P1R deletion. *Po0.05 vs. S1P1Rf/f PEPCK/ mice.
(c) Kidney enhanced green fluorescent protein (EGFP) reporter expression indicative of Cre recombinase activity (green fluorescence) in
ROSA26Sortm4(ACTBtdTomato,EGFP)Luo/J mouse (red fluorescence) crossed with PEPCKCre/ mouse. Representative of three mice generated.
(d) Plasma creatinine from WT (S1P1R
f/f PEPCK/) or from proximal tubule-specific S1P1R null mice (S1P1R
f/f PEPCKCre/) subjected to 30min
of renal ischemia and 24 h of reperfusion. Treatment with a selective A1AR agonist (2-chloro-N6-cyclopentyladenosine (CCPA), 0.1mg/kg,
intraperitoneal (i.p.) 15min before renal ischemia) failed to reduce plasma creatinine level in S1P1R null mice subjected to
renal IR. *Po0.05 vs. vehicle-treated S1P1Rf/f PEPCK/ mice. #Po0.05 vs. CCPA-treated S1P1Rf/f PEPCK/ mice. (e–i) Representative
photomicrographs (e–h, N¼ 4 for each group, magnification  200) and renal injury scores (RISs) (i) of hematoxylin and eosin staining of
kidney sections from WT (S1P1R
f/f PEPCK/) or from proximal tubule-specific S1P1R null mice (S1P1R
f/f PEPCKCre/) subjected to 30min of
renal ischemia and 24 h of reperfusion. Vehicle-treated S1P1R
f/f PEPCK/ mice show severe renal tubular necrosis after renal IR (e, i). CCPA
treatment significantly attenuated renal IR injury in S1P1R
f/f PEPCK/ mice (f, i) but not in S1P1R
f/f PEPCKCre/ mice (h, i). *Po0.05 vs.
vehicle-treated S1P1R
f/f PEPCK/ mice. All data are presented as means±s.e.m. (j) Induction of SK1 in kidneys from WT (S1P1R
f/f PEPCK/)
or from proximal tubule-specific S1P1R null mice (S1P1R
f/f PEPCKCre/) injected with a selective A1AR agonist (CCPA). Representative of three
experiments. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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A1AR–mediated renal protection is again demonstrated in
representative hematoxylin and eosin stains (Figure 4e–h,
magnification  200) and RISs (K). Kidneys from WT
(S1P1R
f/f PEPCK/) mice were protected against renal IR
after CCPA treatment. However, kidneys from proximal
tubule-specific S1P1R null mice (S1P1R
f/f PEPCKCre/)
treated with CCPA showed severe renal necrosis and RISs
after IR. Finally, we demonstrate induction of SK1 in kidneys
from WT (S1P1R
f/f PEPCK/) or from proximal tubule-
specific S1P1R null mice (S1P1R
f/f PEPCKCre/) injected with
a selective A1AR agonist (CCPA, Figure 4j).
Critical role of ABCC1 transporters in A1AR–mediated
renal protection
Next, we tested the hypothesis that induction of SK1 and
subsequent generation of S1P require export of intracellular
S1P to bind to extracellular S1P1R. Previous studies
implicated an important role of ABCC1 transporters
(MRP1) in translocating intracellular S1P to the extracellular
space in several cell types.29–31 We determined that a specific
ABCC1 transporter inhibitor (MK571)29,32,33 completely
inhibited (Cr¼ 2.24þ 0.2 mg/dl, N¼ 4) the CCPA-mediated
renal protection (Cr¼ 1.24þ 0.2 mg/dl, N¼ 6) in mice.
MK571 itself had no effect on renal function after renal IR
injury (Cr¼ 2.25þ 0.2 mg/dl, N¼ 4).
A1AR activation increases SK1 synthesis and induces SK
activity in human proximal tubule (HK-2) cells
HK-2 cells were treated with selective AR agonists (CCPA for
A1AR, CGS21680 for A2aAR, BAY60-6583 for A2bAR, or IB-
MECA for A3AR—all 1 mmol/l) for 5 h (mRNA analysis) or
16 h (protein analysis). We determined that only the A1AR
agonist (CCPA) increased SK1 mRNA and protein expression
and SK activity in HK-2 cells (Figure 5). SK2 mRNA or
protein expression did not change after AR agonist
treatment. Again, we preferentially measured SK1 activity
by adding Triton x-100 in our SK activity assay.
SK and S1P1R signaling is critical for the cytoprotective
effects of A1AR activation in HK-2 cells
HK-2 cells pre-treated with the selective A1R agonist CCPA
were protected against H2O2-induced necrosis (2 mmol/l
H2O2 for 4 h, Figure 6a) and apoptosis (20 ng/ml TNF-a and
10 mg/ml cycloheximide treatment for 16 h, Figure 6b). We
determined that A1AR-mediated protection against necrosis
was blocked by inhibition of SK1 (with SKI-II treatment) or
by blockade of S1P1R (with W146 treatment) (Figure 6a).
Moreover, CCPA-mediated protection against apoptosis was
inhibited by pre-treatment with a selective inhibitor of SK
activity (SKI-II, Figure 6b).
HIF-1a has a critical role in A1AR-mediated SK1 induction
As HIF-1a signaling can induce SK1,34 we tested the
hypothesis that A1AR agonist CCPA induces SK1 via a
HIF-1a-dependent mechanism in HK-2 cells. First, we tested
whether CCPA directly increases nuclear HIF-1a transloca-
tion and subsequent DNA binding in HK-2 cells (Figure 7a).
In HK-2 cells, a selective A1AR agonist CCPA (1mmol/l)
increased nuclear HIF-1a and DNA binding, which was
completely inhibited by 2-methoxyestradiol (2-ME)
(10 mmol/l) or 3-(50-hydroxymethyl-20-furyl)-1-benzylinda-
zole (YC-1) (25 mmol/l) given 30 min before CCPA treatment
(Figure 7a). Furthermore, when HK-2 cells were pre-treated
with inhibitors of HIF-1 signaling (2-ME or YC-1) before
exposure to CCPA (1 mmol/l for 6 h), induction of SK1
mRNA was significantly attenuated (Figure 7b) without
affecting the SK2 expression (data not shown). Finally, we
showed that mice pre-treated with a selective HIF-1a
inhibitor, YC-1 (50 mg/kg i.p.) were not protected against
renal IR injury with CCPA treatment (Figure 7c). Taken
together, these data demonstrate a critical role of increased
nuclear HIF-1a in mediating SK1 induction as well as in vivo
renal protection with A1AR activation.
DISCUSSION
AKI is a frequent and disastrous clinical complication with
high mortality, morbidity, and cost. 2,35 Renal IR injury is a
major cause of AKI for patients subjected to surgical
procedures involving the kidney, heart, liver, or aorta.5,6
Although incompletely understood, renal tubular necrosis,
apoptosis, and inflammation during and after renal IR
contribute significantly to the pathogenesis of ischemic
AKI.36 Cell surface AR activation can attenuate cell death
by reducing necrosis, apoptosis, and inflammation.37
In particular, activation of A1ARs reduces necrosis and
apoptosis whereas A2aAR stimulation leads to tissue protec-
tion via modulation of leukocyte-mediated inflammation.
In the kidney, previous studies showed powerful reno-
protective effects of cell surface AR modulation against renal
IR injury. In particular, activation of A1AR, A2aAR, or A2bAR
was found to be renal protective whereas administration of a
selective A3AR antagonist or a deficiency in A3AR led to renal
protection against IR.9,11,38,39
We previously demonstrated that activation of renal
A1ARs improved plasma creatinine in mice and rats after
renal IR with dramatically reduced proximal tubular necrosis
and apoptosis.9,10 Anti-necrotic and anti-apoptotic effects of
renal A1AR involve activation of extracellular signal-regulated
kinase, Akt and HSP27 through a pertussis toxin-sensitive
G-protein pathway.26,40 Surprisingly, we also identified a
significant renal anti-inflammatory effect of A1AR activation
in vivo.9,11 Unlike the better characterized and traditionally
understood anti-inflammatory mechanisms of A2aAR activa-
tion, the anti-inflammatory mechanisms of A1AR activation
remain unclear. Our data (pro-inflammatory mRNA expres-
sion and neutrophil infiltration, Figure 2g–k) suggest that
A1AR activation may specifically produce anti-inflammatory
effects (in addition to modulating necrosis and apoptosis) via
direct induction and activation of SK1 and S1P synthesis.
A1AR–mediated induction of SK1 and S1P synthesis has
never before described in any organ system and represents
major and novel developments in the understanding
of cytoprotective mechanisms of A1AR activation.
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SK is a conserved lipid kinase that catalyzes the formation
of S1P from sphingosine.41–43 Of the two forms of SK, SK1 is
a well-known mediator of tissue protection (including
protection against IR injury), growth, and survival.19,43,44
In acute lung injury, overexpression of SK1 was protective.45
Furthermore, in cardiac IR injury, SK1 activation has a
potent cytoprotective role and SK1-deficient myocytes had
increased injury after ischemia.19 Along with others, we
previously demonstrated the protective role of SK1 activation
or overexpression against renal IR injury.15,16,23,46
Our studies also show that A1AR–mediated renal protec-
tive effects are dependent on SK1 signaling as mice deficient
in the SK1 enzyme were not protected against renal IR injury
(necrosis and inflammation) with A1AR activation.
We propose that A1AR–mediated SK1 induction would
increase the synthesis of endogenous S1P in renal cortex
and in proximal tubules. S1P is a potent lipid signaling
molecule that activates five S1PRs to regulate diverse
biological effects including cell growth, survival, and
modulation of inflammation.21,47,48 S1P1R activation in
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Figure 5 |A1 adenosine receptor (A1AR) activation increases sphingosine kinase (SK)-1 expression and activity in human
proximal tubule (HK-2) cells. (a, b) Representative bands and densitometric quantification of sphingosine kinase (SK) mRNA (a, reverse
transcription (RT)-PCR) and protein (b, immunoblotting) expression in HK-2 cells treated with vehicle (0.00003% dimethyl sulfoxide (DMSO))
or with selective AR agonists (N¼ 4 for each group). HK-2 cells were treated with 1 mmol/l of selective AR agonist (2-chloro-N6-
cyclopentyladenosine (CCPA) for A1AR, CGS21680 for A2aAR, BAY60-6583 for A2bAR or IB-MECA for A3AR) for 5 h (mRNA analysis) or 16 h
(protein analysis). Note that only the A1AR agonist (CCPA) selective increased SK1 mRNA and protein expression in HK-2 cells without
changing SK2 expression. Data are presented as means±s.e.m. *Po0.05 vs. vehicle treatment. (c) SK activity in HK-2 cells treated with
vehicle (0.00003% DMSO) or with CCPA (1 mmol/l) for 16 h (N¼ 4 for each group). Data are presented as means±s.e.m. *Po0.05 vs.
vehicle treatment. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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particular has been shown to produce tissue protection via
reducing T-lymphocyte-mediated inflammation.13 Activation
of the S1P1Rs on endothelial cells also reduces vascular
permeability, hence maintaining the integrity of the vascular
endothelial cell barrier function.49
Direct S1P1R activation with a selective agonist
23 or
enhanced activation of S1P1R secondary to increased SK1
activity15 produces protection against renal IR in mice. All
five S1PR subtypes can bind to S1P with similar nanomolar
affinities.50 However, as the S1P1R is the most heavily
expressed S1PR subtype in the kidney,51 we propose that
increased SK1-mediated S1P synthesis with A1AR activation
directly mediates renal protection via S1P1R activation. Our
results support this concept as a selective S1P1R antagonist
(W146) or siRNA-mediated deletion of S1P1R completely
blocked the renal protective effects of A1AR activation.
Renal proximal tubules in the corticomedullary junction
(mainly of S3 segments) are highly susceptible to IR injury52
and our studies confirm severe proximal tubule necrosis in
mice subjected to renal IR. A1AR–mediated renal protection
as associated with significantly preserved corticomedullary
junction architecture and reduction in proximal tubule
necrosis. Therefore, we tested the hypothesis that A1AR–
mediated SK1 induction and S1P generation protect against
renal IR by targeting proximal tubular S1P1R. We confirmed
the specific contribution of renal proximal tubule cell S1P1R
in A1AR–mediated renal protection by creating mice with cell
type-specific deletion of S1P1R (with S1P1R
ff PEPCKCre
mice). We also confirmed that induction of renal SK1 was
preserved in mice deficient in proximal tubule S1P1R. Renal
tubular S1P produced from A1AR–SK1 signaling may limit
leukocyte-mediated renal inflammation after IR. Moreover,
A1AR-mediated SK1 induction and S1P1R activation may
also produce direct anti-necrotic and anti-apoptotic effects in
renal proximal tubules as inhibition of SK1 or S1P1R blocked
the cytoprotective effects of CCPA in HK-2 cells in vitro.
S1P has been shown to produce cytoprotection via
activation of cell surface S1PRs or via intracellular mechan-
isms targeting mitochondria, intracellular calcium, or nitric
oxide signaling.53,54 Our data show that either selective S1P1R
blockade (with W146) or renal S1P1R depletion (with siRNA
or with cre-loxP-mediated proximal tubule-specific deletion)
prevented CCPA-mediated renal protection. Furthermore,
blocking export of intracellular S1P to extracellular space
(with MK571-mediated selective ABCC1 transporter
inhibition) abolished CCPA-mediated renal protection
in vivo. Collectively, these data suggest that increased SK1
activity with A1AR activation produces renal protection
via export of intracellular S1P with subsequent activation of
extracellular S1P1R.
We previously demonstrated that renal tubular A1AR
activation resulted in rapid phosphorylation of extracellular
signal-regulated kinase and Akt.7,8 A recent study showed
that the direct renal tubular protective effects of S1P1R
activation are mediated by activation of the Akt/extracellular
signal-regulated kinase pathways.23 S1P also has been shown
to induce HSP27 via the p38 mitogen-activated protein-
kinase and the phosphatidylinositol 3-kinase/Akt pathways in
osteoblasts and aortic smooth muscle cells.55,56 We previously
demonstrated that HSP27 has an important role in
A1AR–mediated renal protection.
40,57 Specifically, we showed
that renal tubular A1AR activation led to induction of HSP27
and a selective inhibitor of HSP27 synthesis attenuated the
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blocks the cytoprotective effects of A1 adenosine receptor
(A1AR) activation in HK-2 cells. (a) Lactate dehydrogenase (LDH)
release as a marker of hydrogen peroxide (H2O2)-induced necrosis
in HK-2 cells (N¼ 6 for each group, expressed as a percentage
of total LDH released). Vehicle (0.00003% dimethyl sulfoxide
(DMSO)) or 2-chloro-N6-cyclopentyladenosine (CCPA) (1 mmol/l)
were applied 6 h before H2O2 treatment, and a selective SK1
inhibitor (SKI-II, 10mmol/l) or a selective S1P1R inhibitor (W146,
1 mmol/l) was given 30min before vehicle or CCPA. A1AR
activation significantly attenuated H2O2-induced necrosis in HK-2
cells and this protective effect was blocked by the inhibition of
SK1 or S1P1R signaling. Data are presented as means±s.e.m.
#Po0.05 vs. vehicle treatment. (b) Representative poly(adenosine
diphosphate-ribose) polymerase (PARP) and caspase-3
fragmentation (N¼ 4 for each group) as indices of HK-2 cell
apoptosis. HK-2 cell apoptosis was induced by tumor necrosis
factor-a (TNF-a) (20 ng/ml) and cycloheximide (10 mg/ml), and
vehicle (0.00003% DMSO) or CCPA (1 mmol/l) was applied 30min
before induction of apoptosis. A selective SK1 inhibitor (SKI-II,
1 mmol/l given 30min before vehicle or CCPA treatment) reduced
the anti-apoptotic effect of A1AR activation in HK-2 cells.
Representative of four independent experiments.
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renal tubular protective effects of A1AR activation. Moreover,
overexpression of renal HSP27 mimicked the protection
conferred by A1AR agonist in vivo renal IR injury.
58 Our
current study indicates that the induction of renal tubular
HSP27 is dependent on A1AR–mediated induction of SK1 as
a selective A1AR agonist (CCPA) failed to induce HSP27 in
SK1-deficient mice. Our findings of A1AR–mediated induc-
tion of SK1 with subsequent activation of S1P1R explain the
similarities in cytoprotective signaling pathways (extracellular
signal-regulated kinase, Akt, and HSP27) generated with
S1P1R or with A1AR activation.
Previous studies have demonstrated that HIF-1a
activation protects against renal IR injury.59 HIF-1 is a
heterodimeric transcription factor composed of an a and a b
subunit.59,60 Under normoxic conditions, prolyl-hydroxyla-
tion followed by ubiquitination of the oxygen-dependent
degradation domain of HIF-1a results in HIF-1a degrada-
tion. With hypoxia or ischemia, HIF-1a stabilizes and
interacts with HIF-1b forming the HIF-1 heterodimer.
Nuclear translocation of HIF-1 allows binding to the
hypoxia-responsive element with subsequent induction of
several cytoprotective genes.
Our findings implicate an important role for HIF-1a in
mediating the induction of SK1 with A1AR activation. We
showed that a selective A1AR agonist caused increased HIF-
1a mRNA production, increased HIF-1a nuclear transloca-
tion, and SK1 induction with subsequently enhanced SK1
activity. We propose that A1AR activation increases binding
of HIF-1a to hypoxia response elements of the SK1 promoter
leading to increase in SK1 protein synthesis and activity.
Consistent with this hypothesis, we showed that selective
HIF-1a blockers (2-ME or YC-1) prevented CCPA-mediated
HIF-1a nuclear translocation as well as induction of SK1 in
HK-2 cells. 2-ME is a natural metabolite of estrogen that
is known to inhibit HIF-1a at the level of translation
independent of effects of estrogen receptors.61 YC-1 is a
selective inhibitor of HIF-1a transcriptional activity.62
Figure 8 summarizes the potential mechanisms of
A1AR–mediated renal protection involving HIF-1a-mediated
SK1 induction, S1P synthesis, and S1P1R activation. Our
findings that A1AR–mediated SK1 induction and S1P release
lead to reduced renal injury represent a significant paradigm
shift and a new direction in A1AR biology. Modulation of an
endogenous tissue protectant to decrease renal IR injury has
important clinical significance with a high therapeutic
potential. Our studies may lead to new therapeutic
approaches with a drug that can reduce all three pathways
of renal cell death (necrosis, apoptosis, and inflammation) to
lessen the clinical perils from AKI and have implications in
organ protection strategies beyond the kidney. Furthermore,
SK1-based renal protection would avoid some of the systemic
side effects (e.g., bradycardia, hypotension, hypothermia, and
sedation) of A1AR agonist therapy. Sphingolipid-based
clinical trials are already ongoing to attenuate organ damage
because of inflammation in renal transplantation and multi-
ple sclerosis.63
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#Po0.05 vs. CCPA-treated group. (c) YC-1 (50mg/kg intraperitoneally) prevented renal protection with CCPA (N¼ 4–6 in each group).
Plasma creatinine was measured from 24 h after reperfusion. *Po0.05 vs. vehicle ischemia–reperfusion (IR). #Po0.05 vs. CCPA IR.
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MATERIALS AND METHODS
Materials
Full systematic chemical names for compounds used in this study
are listed in the Supplementary Table S1. BAY 60-6583 (a selective
A2bAR agonist) as well as Solutol HS 15 (vehicle for BAY 60-6583)
were kind gifts from Bayer AG (Leverkusen, Germany). HIF-1a
inhibitors (YC-1 (an inhibitor of HIF-1a transcriptional activity)
and (17b)-2-methoxyestra-1,3,5(10)-triene-3,17-diol (2-ME, a post-
transcriptional inhibitor of HIF-1a expression)) were purchased
from Enzo Biochem (New York, NY). W146 (a selective S1P1R
antagonist) was obtained from Avanti Polar Lipids (Alabaster, AL)
and a potent SK inhibitor (SKI-II, 4-[[4-(4-chlorophenyl)-2-
thiazolyl]amino]-phenol) was obtained from Cayman Chemicals
(Ann Arbor, MI). Selective A1AR, A2aAR and A3AR agonist ligands
(CCPA, 2-p-(2-carboxyethyl)phenethylamino-50-N-ethylcarboxami-
doadenosine (CGS21680), N6-(3-iodobenzyl)adenosine-50-N-
methyluronamide (IB-MECA), respectively) were obtained from
Tocris (Ellisville, MO). Unless otherwise specified, all other reagents
were purchased from Sigma (St Louis, MO). All drugs
were dissolved in dimethyl sulfoxide and diluted for in vivo
(range¼ 2.5–10%) and in vitro (range¼ 0.001–0.2%) use.
Murine model of renal IR injury
After Institutional Animal Care and Use Committee approval, we
subjected male C57BL/6 (Harlan, Indianapolis, IN; 20–25 g, referred
to as WT mice) as well as SK1/ and SK2/ mice (kindly provided
by Dr RL Proia, NIH, Bethesda, MD; 20–25 g) to 30-min renal IR as
described.26,58 To test the effects of selective A1AR activation on
modulation of renal function after IR, we treated WT mice with a
selective A1AR agonist (CCPA, 0.1 mg/kg i.p.) 15 min before renal
ischemia or sham operation as described.9,11 Some mice were
injected with CCPA without being subjected to surgery to determine
the induction of SK1 mRNA and protein. To test the effects of S1P1R
inhibition, mice were treated with W146 (0.1 mg/kg i.p.) 15 min
before CCPA or vehicle injection as described previously.64 For
in vivo inhibition of HIF-1a transcriptional activity, some mice were
treated with YC-1 (50 mg/kg i.p. 24 h and 15 min before renal
ischemia). To inhibit S1P export via ABCC1 transporter (MRP1),
mice were pre-treated with 1 mg/kg MK571 (an ABCC1-specific
inhibitor)29,32,33 i.p. 30 min before renal ischemia. We collected
kidney (cortex and corticomedullary junction) and plasma 5
(reverse transcription-PCR) and 24 h (immunoblotting, plasma
creatinine and renal necrosis) after renal IR injury to examine the
severity of renal dysfunction.
In vivo intrarenal lentivirus delivery
Lentivirus encoding EGFP or EGFP–huA1AR was generated as
described previously.26 In vivo virus transduction to express human
A1ARs in kidneys of WT, SK1
/, or SK2/ mice was performed
as described by Nakamura et al.65 with slight modifications
as described previously.26 At 48 h after lentivirus injection, we
confirmed transgene expression and processed the kidney for SK
mRNA and protein expression analysis. Some mice were also
subjected to 30 min of renal ischemia and 24 h of reperfusion, 48 h
after EGFP or EGFP–huA1AR lentivirus injection.
siRNA preparation and delivery to mice in vivo
A chemically synthesized 21 nucleotide siSTABLE (stability-
enhanced siRNA) sequences specific for mouse S1P1R were custom
made and purchased from Dharmacon Research (Lafayette, CO) in
20-hydroxyl, annealed, desalted, and dialyzed duplex form for in vivo
use. The siSTABLE is a modified siRNA with improved resistance
against nuclease degradation and enhanced silencing duration
in vivo. The double-stranded sequence for S1P1R siRNA was
50-CCTGTGACATCCTGTACAA-30. Mice were injected with 50mg
of siRNA (100 ml) intravenous 48 h before surgery.
Generation and genotyping of mice with proximal
tubule-specific deletion of S1P1R
We crossed mice carrying the floxed S1P1R gene (S1P1R
ff mice,
provided by Dr RL Proia (NIH)12) with PEPCK-Cre recombinase
mice (provided by Dr Volker Haase, Vanderbilt University).24
S1P1R-floxed mice carrying the PEPCK-Cre gene (S1P1R
f/f
PEPCKCre/) and control mice (S1P1R
f/f PEPCK/) were geno-
typed by tail biopsy PCR using Cre transgene and S1P1R
loxP-specific
primers (Table 1). PEPCK-Cre primers generated a 466-bp
fragment. Flox primers amplified a 250-bp fragment for the S1P1R-
floxed allele and a 200-bp fragment for the S1P1R WT allele. To assess
the specificity of Cre-recombinase expression, PEPCK-Cre mice were
crossed with ROSA26Sortm4(ACTBtdTomato,EGFP)Luo/J mice (Jackson
Labs, Bar Harbor, ME).66 The Rosa mice express red fluorescence
before, and green fluorescence following, Cre-mediated recombination.
Measurement of renal function
Plasma creatinine was measured by an enzymatic creatinine reagent
kit according to the manufacturer’s instructions (Thermo Fisher
Scientific, Waltham, MA). This method of creatinine measurement
largely eliminates the interferences from mouse plasma chromagens
well known to the Jaffe method.67
Mechanisms of A1AR-mediated SK1 induction and renal protection
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Figure 8 |A schematic proposed cellular mechanisms of renal
protection with A1 adenosine receptor (A1AR). Our data
suggest that selective A1AR activation results in increased
hypoxia-inducible factor-1a (HIF-1a) mRNA synthesis, increased
HIF-1a nuclear translocation, and sphingosine kinase (SK)-1
induction with subsequent S1P1R activation. Consistent with this
hypothesis, selective blockade of SK1, or S1P1R inhibits the renal
protective effects of A1AR activation. Furthermore, a selective
ABCC1 transporter inhibitor (MK571) would prevent the export
of intracellular S1P to bind to extracellular S1P1R. Indeed, MK571
prevented the renal protective effects of an A1AR selective
agonist (2-chloro-N6-cyclopentyladenosine (CCPA)).
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Histologic detection of necrosis
Morphological assessment was performed by an experienced renal
pathologist (VDA) who was unaware of the treatment that each
animal had received. An established grading scale of necrotic injury
(0–4, RIS) to the proximal tubules was used for the histopathological
assessment of IR-induced damage as outlined by Jablonski et al.27
and as described previously in our studies.9,11
Reverse transcription PCR analyses
We measured mRNA encoding markers of inflammation
(intercellular adhesion molecule-1 and TNF-a) as well as SK1 and
HSP27 5 h after renal IR as described58,64,68 (Table 1).
Immunohistochemistry for kidney neutrophil infiltration
We measured renal neutrophil infiltration with immuno-
histochemistry 24 h after renal IR as described previously.69
HK-2 cell culture and induction of necrosis and apoptosis
Necrotic injury in HK-2 cells was induced with exposure to 2 mmol/l
H2O2 for 4 h and lactate dehydrogenase released into cell culture
media was measured as described.7 To induce apoptosis, HK-2 cells
were exposed to TNF-a (10 ng/ml) plus cycloheximide (5 mg/ml) for
16 h as described previously.57 Some HK-2 cells were pre-treated
with 1 mmol/l CCPA 6 h before induction of necrosis or apoptosis.
Separate cohorts of HK-2 cells were treated with selective
AR agonists (CCPA, CGS-21680, BAY60-6583, or IB-MECA all
1 mmol/l) for 6 h to test for the induction of SK mRNA and
protein. To inhibit HIF-1a, some HK-2 cells were pre-treated
with 10 mmol/l 2-ME and 25 mmol/l YC-1 30 min before CCPA
treatment.
Immunoblotting analyses of kidney tissue and HK-2 cells
Mouse kidney cortical tissues (including corticomedullary junction)
and HK-2 cell lysates were collected for immunoblotting analyses
of SK1, SK2, and b-actin (internal protein loading control) as
described previously.64,68 The primary antibodies for human and
mouse SK2 were obtained from Abcam (Cambridge, MA). The
primary antibody for human and mouse b-actin was obtained from
Sigma. The secondary antibody (goat anti-rabbit and anti-mouse
immunoglobulin G-conjugated to horseradish peroxidase used at
1:5000 dilution) was detected with enhanced chemiluminescence
immunoblotting detection reagents (Amersham, Piscataway, NJ),
with subsequent exposure to a CCD camera coupled to a UVP
Bio-imaging System (Upland, CA) and a personal computer.
Table 1 | Primers used to amplify mRNAs based on published GenBank sequences for mice
Primers Accession number Sequence (sense/antisense)
Product
size (bp)
Cycle
number
Annealing
temperature
(1C)
Mouse S1P1R NM_007901 5
0-CGGTGTAGACCCAGAGTCCT-30 393 20 64
50-AGCAGCAGATGAGAATGAAC-30
Mouse S1P2R NM_010333 5
0-AAAACCAACCACTGGCTGTC-30 317 25 60
50-GAGTGGAACTTGCTGTT-30
Mouse S1P3R NM_010101 5
0-AAGCCTAGCGGGAGAGAAAC-30 452 22 64
50-GGCAATCAAAACCATCAGGT-30
Mouse S1P4R NM_010102 5
0-GCAGAAGTCTCCACGTCCTC-30 403 23 62
50-GCTGAGTGACCGAGAAGTCC-30
Mouse S1P5R NM_053190 5
0-ACACCAAATGCCCAGCTTAC- 30 335 32 62
50-ACCAAGAGCACAGCCAAGTTC-30
Mouse ICAM-1 X52264 50-TGTTTCCTGCCTCTGAAGC-30 409 21 60
50-CTTCGTTTGTGATCCTCCG-30
Mouse TNF-a X02611 50-TACTGAACTTCGGGGTGATTGGTCC-30 290 24 65
50-CAGCCTTGTCCCTTGAAGAGAACC-30
Mouse HSP27 NM_024441 50-CCTAAGGTCTGGCATGGTA-30 373 25 66
50-AGGAAGCTCGTTGTTGAAGC-30
Mouse SK1 NM_011451 (variant 1) 50-GATGCATGAGGTGGTGAATG-30 337 22 64
NM_025367 (variant 2) 50-GCCCACTGTGAAACGAATC-30
Human SK1 NM_021972 (variant 1) 50-ATCTCCTTCACGCTGATGC-30 330 26 66
NM_182965 (variant 2)
NM_001142601 (variant 3)
NM_001142602 (variant 4)
50-GTGCAGAGACAGCAGGTTCA-30
Human SK2 NM_020126 (variant 1) 50-GGAGGAAGCTGTGAAGATGC-30 482 22 66
NM_001204158 (variant 2)
NM_001204159 (variant 3)
NM_001204160 (variant 4)
50-GCAGGTCAGACACAGAACGA-30
Mouse and
human GAPDH
M32599 50-ACCACAGTCCATGCCATCAC-30 450 15 65
50-CACCACCCTGTTGCTGTAGCC-30
Cre transgene 5-TGGGCGGCATGGTGCAAGTT-3 466 30 61
5-CGGTGCTAACCAGCGTTTTC-3
S1P1R
loxP 50-GAGCGGAGGAAGTTAAAAGTG-30 WT: 200
LOX: 250
45 56
50-CCTCCTAAGAGATTGCAGCAA-30
Abbreviations: bp, base pair; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HSP27, heat shock protein 27; ICAM-1, intercellular adhesion molecule-1; S1PR,
sphingosine-1-phosphate receptor; SK, sphingosine kinase; TNF-a, tumor necrosis factor alpha.
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HK-2 cell HIF-1a DNA-binding assay
Nuclear extracts from HK-2 cells were prepared using the
TransFactor Extraction Kit (BD Biosciences Clontech, Palo Alto,
CA) according to the manufacturer’s instructions. HIF-1a
DNA-binding activity in nuclear extracts was determined using a
TransFactor Family Colorimetric kit specific for HIF-1a (BD
Biosciences Clontech) according to the manufacturer’s instructions.
HK-2 cells were treated with 1 mmol/l CCPA for 6 h. To inhibit
HIF-1a, some HK-2 cells were pre-treated with 10mmol/l 2-ME and
25 mmol/l YC-1 30 min before CCPA treatment.
SK activity assay
SK activity was measured as described previously.15 Briefly, kidney
tissues from mice or HK-2 cells were collected and homogenized in
cell lysate buffer (100 mmol/l sucrose, 1 mmol/l ethyleneglycol
tetraacetic acid, 20 mmol/l 4-morpholinepropanesulfonic acid, pH
7.4, 5% Percoll, 0.01% digitonin, protease (Calbiochem, La Jolla,
CA) and phosphatase inhibitors) on ice. After a 1000 g spin for
15 min to pellet cellular debris, protein concentrations were
determined and SK activity was measured as described by Vessey
et al.25 To preferentially measure SK1 activity, we supplemented the
assay buffer with 0.5% Triton X-100.
Isolation of mouse kidney proximal tubules cells
Mouse kidneys were removed, rinsed in phosphate-buffered saline
containing 0.5% bovine serum albumin and 2 mmol/l EDTA
(GIBCO, Grand Island, NY), minced and digested in collagenase
A (1 mg/ml, Sigma) at 37 1C for 45 min with occasional agitation.
The cellular digest was filtered through a nylon mesh, centrifuged at
600 g for 10 min, and washed twice. Mouse kidney proximal tubules
were isolated according to the method of Vinay et al.28 using Percoll
density gradient separation.
Statistical analysis
The data were analyzed with Student’s t-test when comparing means
between two groups. One-way analysis of variance plus Tukey’s
post hoc multiple comparison test was used when comparing multiple
groups. Two-way analysis of variance plus Bonferroni posttest was
used to test the effects of sham operation or renal IR injury on
different mouse strains or treatment groups. The ordinal values of the
RISs were analyzed by the Mann–Whitney nonparametric test. In all
cases, a probability statistic o0.05 was taken to indicate significance.
All data are expressed throughout the text as means±s.e.m.
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